ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1337

Fatigue Levels Are Not Associated with Inflammatory Activity, but with Subjective Outcomes: Results from a Longitudinal Study of Patients with Rheumatoid Arthritis Initiating bDMARD Therapy

Hilde Hammer1, Brigitte Michelsen 2, Joe Sexton 3, Sella Provan 1, Till Uhlig 4 and Tore Kvien 4, 1Diakonhjemmet Hospital, Oslo, Norway, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 3Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 4Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Fatigue, rheumatoid arthritis (RA) and ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Fatigue is a sensation of weakness and lack of energy which is common in patients with rheumatoid arthritis (RA), contributing to reduced quality of life. Fatigue may be associated with inflammatory activity as well as with bio-psycho-social factors. However, these associations may be changed during effective treatment. The present study explores this issue by assessing the cross-sectional and longitudinal associations between fatigue and inflammatory markers (ultrasound, clinical and C-reactive protein (CRP) assessments) as well as bio-psycho-social factors.

Methods: A total of 208 patients with established RA (mean (SD) age 53 (13) years, disease duration 10 (9) years, 81% women, 79% anti-CCP positive) were examined when initiating biologic DMARDs at baseline as well as after 1, 2, 3, 6 and 12 months, including  fatigue (0-10, as part of the RAID score), patient-reported outcome measures (PROMs) (joint pain VAS, patient’s global disease activity VAS (PGA), MHAQ, pain catastrophizing , SF-36 Mental Health  scale score),  clinical examinations (performed by a study nurse including examiner’s global disease activity VAS (EGA), 28 tender and swollen joint counts  (28TJC, 28SJC)) and CRP. Ultrasound examinations (semi-quantitative scoring (0-3)) of grey scale (GS) and power Doppler (PD)) were performed of 36 joints and 4 tendons by one rheumatologist (HBH; Siemens Acuson Antares, excellence version, 5-13 MHz probe). Correlations were assessed by Spearman’s rho.  The predictive value of baseline fatigue on ultrasound, clinical and laboratory assessments as well as PROMs were explored for all follow-up visits by use of multiple linear regression analysis with adjustment for demographic values (age, sex and disease duration).

Results: Fatigue levels diminished during follow-up (baseline median (IQR) 5 (3-7), 12 months 2 (1-5)). Table 1 shows the strong cross-sectional correlations between fatigue and scores of PROMs, low correlations with EGA/SJC/CRP and lack of correlations with ultrasound scores. Baseline fatigue levels predicted scores of PROMs at all examinations (table 2). No/low associations were found between baseline fatigue and 28SJC/EGA/sum score GS and PD at follow-up.

Conclusion: Fatigue was strongly correlated with all PROMs but had low/no associations with objective measures of inflammation. Baseline fatigue predicted all the subjective outcomes at follow-up, but not CRP, SJC or ultrasound. Thus, fatigue was presently not associated with inflammatory activity, but with subjective outcomes.


14.05.19_Table 1


14.05.19_Table 2


Disclosure: H. Hammer, None; B. Michelsen, Novartis, 2, 5; J. Sexton, None; S. Provan, None; T. Uhlig, None; T. Kvien, AbbVie, 2, 8, Biogen, 5, 8, Biogen, Egis, Eli Lilly, Hikma, Mylan, Novartis/Sandoz, Oktal, Hospira/Pfizer, Sanofi and UCB, 5, BMS, 8, Celltrion, 8, Egis, 5, 8, Eli Lilly, 5, 8, Hikma, 5, 8, Hospira/Pfizer, 2, 5, 8, MSD, 2, 8, Mylan, 5, 8, Novartis, 8, Novartis/Sandoz, 5, 8, Oktal, 5, 8, Orion Pharma, 8, Roche, 2, 8, Sandoz, 8, Sanofi, 5, 8, UCB, 5, 8.

To cite this abstract in AMA style:

Hammer H, Michelsen B, Sexton J, Provan S, Uhlig T, Kvien T. Fatigue Levels Are Not Associated with Inflammatory Activity, but with Subjective Outcomes: Results from a Longitudinal Study of Patients with Rheumatoid Arthritis Initiating bDMARD Therapy [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/fatigue-levels-are-not-associated-with-inflammatory-activity-but-with-subjective-outcomes-results-from-a-longitudinal-study-of-patients-with-rheumatoid-arthritis-initiating-bdmard-therapy/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fatigue-levels-are-not-associated-with-inflammatory-activity-but-with-subjective-outcomes-results-from-a-longitudinal-study-of-patients-with-rheumatoid-arthritis-initiating-bdmard-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology